Tirzepatide, the blockbuster GLP-1 medicine known as Mounjaro for diabetes and Zepbound for weight loss, cut the odds that an obese, prediabetic person will develop diabetes by 94%, a new trial shows.
through the treatment period, with adults on the 15-milligram dose experiencing a 22.9% average decrease in body weight compared to 2.1% for placebo," the company said in a news release issued Tuesday.received a "dummy" placebo injection weekly or an injection of either 5 mg, 10 mg or 15 mg of tirzepatide for 176 weeks .rose along with the dose of tirzepatide: 15.4% of starting weight lost for those taking the 5 mg dose, 19.9% with 10 mg and 22.9% with the 15 mg dose.
According to Lilly, during the 17 weeks after ceasing treatment, "those who had discontinued from tirzepatide began to regain weight and had some increase in the progression toWhat about side effects? "The most frequently reported adverse events were typically gastrointestinal-related and generally mild to moderate in severity," according to the company. Gastrointestinal complaints includedLearn about type 2 diabetes warning signs, symptoms, diagnosis, and treatment options.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Mounjaro/Zepbound Drastically Cuts Risk Of Type 2 Diabetes, Eli Lilly Report SuggestsArianna Johnson is a reporter on the Forbes news desk who covers explainers and trends, with a frequent focus on health and science. She joined Forbes in 2022 and works in Texas. Johnson has covered prominent weight loss drugs like Ozempic and Wegovy, the health effects of the artificial sweetener aspartame and the impacts of the Covid vaccines.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterEli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker. Lilly also hiked its forecast for the year well beyond Wall Street expectations as newer drugs like Zepbound built momentum.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterMounjaro sales more than tripled in the quarter to nearly $3.1 billion. Zepbound, which is made from the same molecule, brought in $1.2 billion two quarters after regulators approved the drug.
Read more »
Eli Lilly raises forecast after boost in Zepbound, Mounjaro salesEli Lilly and Co. reported strong second-quarter results, beating Wall Street estimates and prompting the company to raise its full-year revenue forecast by $3 billion.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker.
Read more »